主讲人： 朱耀球 博士、教授
主讲人单位：美国德克萨斯大学厄尔巴索分校
时  间：2015.11.19   15:30-17：00
地  点：实验楼116会议室
主  办：化学系
主讲人简介：Dr. Zhu obtained his B.S. of Chemistry in 2001 at Peking University in Beijing, China. Under the supervision of Prof. Richard B. Silverman (inventor of Pfizer’s blockbuster drug Lyrica) in the Department of Chemistry at Northwestern University, he conducted doctoral research on enzyme chemistry and got his Ph.D. in 2006. With a strong interest in drug discovery, he then joined Abbott Laboratories as a senior research scientist. Dr. Zhu conducted “structure and drug-like property relationship” studies for over 20 internal R&D projects including a program that has eventually yielded the recently approved HCV drug Viekira Pak (AbbVie). After worked at Abbott for over two years, Dr. Zhu resigned and founded his own contract research company, MetabQuest. He independently built a drug metabolism and medicinal chemistry lab in Beijing, China. He and his team have worked with pharmaceutical companies and research institutes on various medicinal chemistry projects and preclinical studies. In addition, Dr. Zhu’s lab has participated in several translational drug discovery research collaborations involving Harvard Medical School, University of Pittsburgh, Northwestern University, China Pharmaceutical University, Cambria Biosciences, etc. To pursue the long-term goal of becoming a medicinal chemistry professor, since 2012, Dr. Zhu has closed his company and devoted his lab to academic research projects, including “Investigation of the clinical drawbacks of Plavix (BMS & Sanofi) and discovery of novel antiplatelet agents”. Recently he accepted a tenure-track assistant professor position at Department of Chemistry in University of Texas at El Paso. Dr. Zhu’s academic research focuses on novel methodologies for biomedical research and cancer drug discovery.